Abstract
Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma, which has distinct clinical and molecular features, many of which are similar to that of nodular sclerosing/classical Hodgkin lymphoma. Anthracycline-based chemotherapy forms the foundation for treatment of this lymphoma. This review will discuss controversial topics that warrant further study, such as the superiority of third generation regimens over CHOP-based regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone), the use of involved field radiotherapy, and the assessment of clinical response by positron emission tomography scans.
MeSH terms
-
Adult
-
Anthracyclines / administration & dosage
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Gene Expression Profiling
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / genetics
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Male
-
Mediastinal Neoplasms / drug therapy*
-
Mediastinal Neoplasms / genetics
-
Mediastinal Neoplasms / pathology
-
Prednisolone / administration & dosage
-
Randomized Controlled Trials as Topic
-
Rituximab
-
Sex Distribution
-
Vincristine / administration & dosage
Substances
-
Anthracyclines
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisolone